scholarly journals Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Nicolò Martini ◽  
Stefania Rizzo ◽  
Cristiano Sarais ◽  
Alberto Cipriani

Abstract Background Amyloidosis is a rare systemic disease due to the extracellular tissue deposition of a fibrillar-shaped misfolded protein, called amyloid. Only two types of proteins commonly affect the heart leading to an infiltrative cardiomyopathy: immunoglobulin light chain and transthyretin (TTR) cardiac amyloidosis (CA). Despite the promising role of emerging imaging modalities, such as strain echocardiography, cardiac magnetic resonance and bone scintigraphy, its diagnosis is still often missed or delayed due to their inherent limitations and to a nonspecific clinical scenario with frequent concomitance of cardiac comorbidities. The gold standard for a definite diagnosis still remains endomyocardial biopsy, but in rare cases Congo Red staining could provide false negative results, as in our case, requiring immunoelectron microscopy. Case presentation A middle-aged male adult presented to the emergency department for relapse of heart failure. Echocardiography and cardiac magnetic resonance, along with the history of bilateral carpal tunnel syndrome, were suspicious for TTR-CA. The diagnosis, however, was hampered by concomitant cardiac comorbidities and conflicting results of imaging modalities. In fact bone scintigraphy was negative, as well as Congo Red Staining on myocardial tissue samples obtained by endomyocardial biopsy. Given the high clinical suspicion, immunoelectron microscopy was performed, showing TTR amyloid fibrils deposits, that confirmed the diagnosis. A genetic analysis excluded and hereditary form. The patient was then referred to a specialist center for specific treatment. Conclusions This is a rare case of a TTR-CA with a negative Bone Scintigraphy and Congo red staining, which demonstrated that CA is frequently misdiagnosed because of the low specific clinical manifestations and the results of imaging modalities that sometimes could be misleading, with subsequent delayed diagnosis and correct treatment.

Author(s):  
Angela Pucci ◽  
Alberto Aimo ◽  
Veronica Musetti ◽  
Andrea Barison ◽  
Giuseppe Vergaro ◽  
...  

Background The relative contribution of amyloid and fibrosis to extracellular volume expansion in cardiac amyloidosis (CA) has never been defined. Methods and Results We included all patients diagnosed with amyloid light‐chain (AL) or transthyretin cardiac amyloidosis at a tertiary referral center between 2014 to 2020 and undergoing a left ventricular endomyocardial biopsy. Patients (n=37) were more often men (92%), with a median age of 72 years (interquartile range, 68–81). Lambda‐positive AL was found in 14 of 19 AL cases (38%) and kappa‐positive AL in 5 of 19 (14%), while transthyretin was detected in the other 18 cases (48%). Amyloid deposits accounted for 15% of tissue sample area (10%–30%), without significant differences between AL and transthyretin amyloidosis. All patients displayed myocardial fibrosis, with a median extent of 15% of tissue samples (10%–23%; range, 5%–60%), in the absence of spatial overlap with amyloid deposits. Interstitial fibrosis was often associated with mild and focal subendocardial fibrosis. The extent of fibrosis or the combination of amyloidosis and fibrosis did not differ significantly between transthyretin amyloidosis and AL subgroups. In 20 patients with myocardial T1 mapping at cardiac magnetic resonance, the combined amyloid and fibrosis extent displayed a modest correlation with extracellular volume ( r =0.661, P =0.001). The combined amyloid and fibrosis extent correlated with high‐sensitivity troponin T ( P =0.035) and N‐terminal pro‐B‐type natriuretic peptide ( P =0.002) serum levels. Conclusions Extracellular spaces in cardiac amyloidosis are enlarged to a similar extent by amyloid deposits and fibrotic tissue. Their combination can better explain the increased extracellular volume at cardiac magnetic resonance and circulating biomarkers than amyloid extent alone.


Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Bethany A Austin ◽  
Scott Flamm ◽  
Rene Rodriguez ◽  
Carmela Tan ◽  
W.H. Wilson Tang ◽  
...  

In patients with suspected cardiac amyloidosis (CA), endomyocardial biopsy (EMB) provides definitive diagnosis. On delayed hyper-enhancement cardiac magnetic resonance (DHE-CMR), CA has a characteristic diffuse enhancement of the subendocardium extending to adjacent myocardium. We sought to determine the accuracy of DHE-CMR, as compared to standard noninvasive parameters, in the diagnosis of patients with suspected CA who underwent EMB. A total of 37 consecutive patients (mean age 60 years, 70 % men, 57 % with NYHA class > 2) with suspected CA underwent electrocardiography (ECG), transthoracic echocardiography (TTE), DHE-CMR (Siemens 1.5 T scanner, Erlangen, Germany) and EMB between 1/05 and 4/08. Low voltage on ECG was defined as the sum of S wave in lead V1 + R wave in lead V5 or V6 < 15mm. Standard TTE (including tissue Doppler) parameters and myocardial performance index (MPI) [(isovolumic contraction time + isovolumic relaxation time)/ejection time] were recorded. CMR was considered positive in the presence of DHE of the subendocardium extending to the adjacent myocardium. Fifteen patients had EMB-positive CA, while 22 had negative EMB. Using EMB as the gold standard, there was 1 false-positive and 1 false-negative CMR. Sensitivity and specificity of DHE-CMR for CA was 93% and 95%, and, positive predictive value (PV) and negative PV of DHE-CMR in the diagnosis of CA were 93 % and 95 % respectively. Logistic regression analysis demonstrating the association between EMB-positive CA and various noninvasive parameters is shown in the Table . DHE-CMR is highly accurate in noninvasive diagnosis of EMB-positive CA as compared to standard ECG and TTE criteria. Incremental prognostic value of DHE-CMR in CA for clinical outcomes needs to be determined. Table: Logistic univariate regression analysis testing the association between endomyocardial biopsy proven cardiac amyloidosis and various noninvasive imaging parameters.


Author(s):  
Brendan L. Eck ◽  
Nicole Seiberlich ◽  
Scott D. Flamm ◽  
Jesse I. Hamilton ◽  
Abhilash Suresh ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Giovanni Peretto ◽  
Alberto M. Cappelletti ◽  
Roberto Spoladore ◽  
Massimo Slavich ◽  
Stefania Rizzo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document